Spit test may predict lung injury severity in kids
NCT ID NCT07380373
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 37 children with acute respiratory distress syndrome (ARDS) who are on breathing machines. Researchers want to see if measuring certain inflammation markers in saliva works as well as measuring them in fluid from the lungs. If saliva works, it could lead to a simpler, less invasive way to track disease severity and predict outcomes like recovery time or survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 37 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of pediatric patients diagnosed with mild to moderate acute respiratory distress syndrome (ARDS) who are admitted to the pediatric intensive care unit (PICU) and on mechanical ventilation to decrease the hazards of bronchoscopy on sever patients with ARDS
- Ages
-
1 year to 10 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical diagnosis of Pediatric Acute Respiratory Distress Syndrome (ARDS) * Age range: 1 month to 18 years * Requirement for invasive mechanical ventilation * Availability of salivary and bronchoalveolar lavage (BAL) samples within 24 hours of ARDS diagnosis * Informed consent obtained from parent or legal guardian Exclusion Criteria: * Pre-existing chronic lung disease (e.g., cystic fibrosis, bronchopulmonary dysplasia) * Known immunodeficiency or current immunosuppressive therapy * Active malignancy or receipt of chemotherapy within the past 6 months * Severe congenital anomalies incompatible with survival * Refusal or inability to obtain informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (acute respiratory distress syndrome) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ain shams university, Cairo
Cairo, 11517, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a different ventilator mode help ARDS patients breathe on their own faster?
- Can a smarter ventilator setting spare damaged lungs on ECMO?
- Can varying breath size protect lungs on a ventilator?
- Can matching drugs to biology beat ARDS?
- Immune cell infusion aims to free ARDS patients from ventilators
- New ventilation strategy aims to reduce lung damage in severe pneumonia